San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Bionano Genomics is raising $41,850,386.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Erik Holmlin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bionano Genomics
Bionano Genomics, Inc., a genome analysis company, provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. Its Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables scientists and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. The company also provides diagnostic testing for those with autism spectrum disorder and other neurodevelopmental disabilities. In addition, it offers an agnostic cross-platform data interpretation and clinical reporting software that integrates next-generation sequencing and microarray data, and provides visualization of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome for a fully integrated analysis in one view. The company was founded in 2006 and is headquartered in San Diego, California.

To learn more about Bionano Genomics, visit http://www.bionanogenomics.com/

Contact:
Erik Holmlin, President and Chief Executive Officer
858-888-7600
eholmlin@bionanogenomics.com
https://www.linkedin.com/in/eholmlin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved